Clinical trials: Blood Pressure Monitoring, Ambulatory
Diabetes Mellitus, Type 2
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
The purpose of this study is to assess the effects of 2 doses of LY2189265 on blood pressure and heart rate using 24-hour ambulatory blood pressure monitoring (ABPM), in participants with type 2 diabetes mellitus treated with…
- Trial name
- NCT01149421
- Testing
- LY2189265
- Where
- 76 sites in United States, Argentina and 6 more
- Volunteers
- 755 people
- Sponsor
- Eli Lilly and Company
Osteoarthritis, Hypertension
To Assess the Effect of Naproxcinod Versus Naproxen and Ibuprofen on Arterial Blood Pressure in Osteoarthritis Patients With Controlled Essential Hypertension
To assess the effect of naproxcinod vs. naproxen and ibuprofen on arterial blood pressure in patients with osteoarthritis and controlled essential hypertension
- Trial name
- HCT3012-X-112 (NCT00662896)
- Testing
- naproxcinod 375 mg bid, naproxcinod 750 mg bid, naproxen 250 mg bid
- Where
- 57 sites in United States
- Volunteers
- 300 people
- Sponsor
- NicOx
Hypertension
Management of Newly Diagnosed and Uncontrolled Hypertension With Fixed-Dose Combination of Perindopril/Amlodipine and Perindopril/Indapamide/Amlodipine
PRECIOUS Study aims to evaluate the efficacy and safety of therapy with fixed-dose combination (FDC) of perindopril/amlodipine (Amlessa®) and FDC of perindopril/indapamide/amlodipine (Co-Amlessa®) on blood pressure reduction in…
- Trial name
- PRECIOUS (NCT03738761)
- Testing
- Amlessa®, Co-Amlessa®
- Where
- 34 sites in Armenia, Croatia and 5 more
- Volunteers
- 471 people
- Sponsor
- KRKA
Osteoarthritis, Controlled Hypertension
Safety and Efficacy of Lumiracoxib in Patients With Osteoarthritis and With Controlled Hypertension
This study will investigate the effect on ambulatory blood pressure of lumiracoxib 100 mg once daily versus ibuprofen 600 mg three times a day in osteoarthritis patients with controlled hypertension.
- Trial name
- NCT00267176
- Testing
- lumiracoxib
- Where
- 2 sites in United States, Germany
- Volunteers
- 1,020 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
A Trial Comparing MICARDIS® (Telmisartan) and COZAAR® (Losartan) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM)
The primary aim of the trial is to compare the influence of MICARDIS® (telmisartan 40-80 mg) and COZAAR® (losartan 50-100 mg) in lowering ambulatory diastolic blood pressure (DBP) during the last 6 hours of the 24-hour dosing…
- Trial name
- NCT02200640
- Testing
- High dose of Micardis®, once daily, Low dose of Micardis®, once daily, Low dose of COZAAR®, once daily
- Volunteers
- 333 people
- Sponsor
- Boehringer Ingelheim
Essential Hypertension
Antihypertensive Effect of Rostafuroxin Compared With Losartan in Hypertensive Patients Bearing Specified Gene Mutations
The principal aim of the study is to demonstrate that Rostafuroxin is able to induce a more pronounced reduction of arterial blood pressure respect to Losartan, in hypertensive patients carrying at least one of the pre-specified…
- Trial name
- NCT01320397
- Testing
- Rostafuroxin, Losartan
- Where
- 26 sites in Ireland, Italy and 1 more
- Volunteers
- 240 people
- Sponsor
- RostaQuo S.p.A.
Hypertension
Study to Evaluate Efficacy of Micardis® (Telmisartan) and Valsartan in Patients With Mild-to-moderate Hypertension After Missing One Dose Using Ambulatory Blood Pressure Monitoring
The primary aim of the trial is to compare telmisartan 80 mg to valsartan 160 mg in lowering diastolic blood pressure in patients who missed a dose of their medication, as measured by ABPM (change from baseline in mean DBP over…
- Trial name
- NCT02242318
- Testing
- Telmisartan, Valsartan
- Volunteers
- 440 people
- Sponsor
- Boehringer Ingelheim
Chronic Spontaneous Urticaria
A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.
The purpose of this study was to assess the effect of remibrutinib 25 mg twice a day (b.i.d.) open-label on Systolic Blood Pressure (SBP) measured as a change in 24-hour weighted average SBP from baseline to Week 4 assessed by…
- Trial name
- NCT05795153
- Testing
- LOU064
- Where
- 44 sites in United States, Argentina and 8 more
- Volunteers
- 144 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes, Hypertension
18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics
To determine if olmesartan plus amlodipine combination therapy alone and with hydrochlorothiazide will be safe and effective to reduce high blood pressure in hypertensive, type 2 diabetic subjects.
- Trial name
- NCT00654745
- Testing
- Amlodipine, amlodipine / olmesartan medoxomil combination, Hydrochlorothiazide
- Where
- 21 sites in United States
- Volunteers
- 207 people
- Sponsor
- Daiichi Sankyo
Hypertension
Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension
The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), co-administered with amlodipine in treating individuals with essential hypertension, compared to treatment with amlodipine…
- Trial name
- NCT00591266
- Testing
- Azilsartan Medoxomil and amlodipine, Amlodipine
- Where
- 50 sites in United States
- Volunteers
- 566 people
- Sponsor
- Takeda
Hypertension
Effects of Doxazosin Gastrointestinal Therapeutic System on Ambulatory Blood Pressure and Cardiovascular Risk Factors in Uncontrolled Hypertensive Patients
The primary objective was to determine the effects of the Gastrointestinal Therapeutic System (GITS) formulation of Doxazosin when used in combination therapy with the 5 major classes of antihypertensive agents as measure by…
- Trial name
- NCT00646841
- Testing
- Doxazosin gastrointestinal therapeutic system (GITS)
- Where
- 7 sites in Italy, Spain and 1 more
- Volunteers
- 89 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypogonadism, Male
Vogelxo(R) ABPM Study in Hypogandal Men
A Phase 4 ABPM study in Hypogonadal Men
- Trial name
- NCT04558567
- Testing
- Vogelxo
- Where
- 7 sites in United States
- Volunteers
- 122 people
- Sponsor
- Upsher-Smith Laboratories
Hypertension
Effects of Telmisartan by Ambulatory Blood Pressure Monitoring (ABPM) in Chinese Patients With Mild to Moderate Essential Hypertension
To assess the trough/peak ratio of 40 mg Telmisartan tablet by ambulatory blood pressure monitoring in Chinese patients with mild to moderate essential hypertension
- Trial name
- NCT02206659
- Testing
- Telmisartan
- Volunteers
- 20 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension
The purpose of this study is to evaluate the effectiveness and safety of azilsartan medoxomil compared to placebo, once daily (QD), in African-American participants with essential hypertension.
- Trial name
- NCT00591253
- Testing
- Azilsartan medoxomil
- Where
- 64 sites in United States, Puerto Rico
- Volunteers
- 413 people
- Sponsor
- Takeda
Hypertension
Prospective Randomised Investigation of the Safety and Efficacy of Micardis® vs Ramipril Using ABPM
The primary objective of this study is to demonstrate that telmisartan 80 mg (MICARDIS®) is at least as effective and possibly superior to ramipril 5mg and 10mg in lowering mean ambulatory diastolic blood pressure (DBP) and…
- Trial name
- PRISMA (NCT00274612)
- Testing
- Telmisartan, Ramipril
- Where
- 62 sites in Austria, France and 6 more
- Volunteers
- 801 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Russian Study of the Efficacy and Safety of Tarka in Patients With Hypertension
This study will investigate antihypertensive activity and safety profile of Tarka in Russian hypertension patients by ambulatory blood pressure measurement (ABPM)
- Trial name
- NCT00235001
- Testing
- trandolapril/verapamil
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Abbott
Hypertension
Telmisartan Versus Amlodipine in Patients With Mild-to-Moderate Hypertension
The primary aim of the trial is the effect of telmisartan versus amlodipine in lowering ambulatory diastolic and/or systolic blood pressures in the last six hours of the dosing interval in patients with mild-to-moderate…
- Trial name
- NCT02177409
- Testing
- Telmisartan, Amlodipine
- Volunteers
- 431 people
- Sponsor
- Boehringer Ingelheim
Blood Pressure
Clinical Trial of Wrist Ambulatory Blood Pressure Monitor in Conformance With the ISO 81060-2:2018+AMD1:2020+AMD2:2024.
The accuracy and safety of the Wrist Ambulatory Blood Pressure Monitor (Model: RIV-B10) were assessed according to the requirements of ISO 81060-2:2018+AMD1:2020+AMD2:2024.
- Trial name
- NCT07713576
- Testing
- Wrist Ambulatory Blood Pressure Monitor/mercury sphygmomanometer
- Where
- China
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Huawei Device Co., Ltd
Hypertension
Study to Evaluate the Trough and Peak Effect of Once Daily Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg (Micardis Plus) by Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Essential Hypertension
To evaluate the trough and peak effect of once daily MICARDIS PLUS (Telmisartan 80 mg/hydrochlorothiazide 12.5 mg) by 24 ABPM in patients with mild to moderate essential hypertension.
- Trial name
- NCT00257491
- Testing
- Telmisartan, Telmisartan/HCTZ
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Telmisartan Compared to Losartan + Hydrochlorothiazide in Patients With Mild-to-moderate Essential Hypertension
The general aim and clinical objective of this trial is to determine the effect of telmisartan 80 mg compared to losartan 50 mg + HCTZ (Hydrochlorothiazide) 12.5 mg on reduction of blood pressure (BP) in patients with mild to…
- Trial name
- NCT02183701
- Testing
- Telmisartan, Losartan + Hydrochlorothiazide
- Volunteers
- 715 people
- Sponsor
- Boehringer Ingelheim